AZ and SK's Sidapvia is approved, first collab in 10 yrs
By Jung, Sae-Im | translator Kim, Jung-Ju
23.07.19 12:10:53
가나다라
0
‘Sidapvia,’ which was jointly developed by AZ and SK Chemicals, is approved
Combined the original Forxiga and No.1 DPP-4 inhibitor ingredient...increases line-up
Past Hanmi-Sanofi collaborated ‘Rovelito’ a success... posts sales of KRW 78 billion
The first collaboration between a domestic company and big pharma has come to fruition. This is the first collaboration made in almost a decade since the development of Rovelito. Whether AstraZeneca, which is trying to increase the use of its diabetes treatment 'Forxiga' in clinics in Korea, and SK Chemicals, which is trying to increase production through global expansion with AstraZeneca, will create a synergistic effect is gaining attention.
According to industry sources on the 19th, AstraZeneca and SK Chemicals succeeded in codeveloping a combination treatment for Type 2 diabetes. The drug, Sidapvia, is a combination of the SGLT-2 inhibitor dapagliflozin and DPP-4 inhibitor sitagliptin.
Jung, Sae-Im (same@dailypharm.com)
If you want to see the full article, please JOIN US (click)